Ozempic is no longer alone in the ring. It faces strong competition from Zepbound in America. Pharma giant AstraZeneca is also joining us with its own version. And Big Pharma is preparing for a boxing match at the highest level. Who has the best cards? And what’s in the pipeline? “Ozempic tablets will change everything,” says top cardiologist Pedro Brugada to HLN.
ttn-3
The Ozempic war starts: new version is worth 100 billion dollars
